期刊文献+

食管鳞癌组织和引流淋巴结中IDO和BIN1的表达及其临床意义 被引量:2

Expressions of IDO and BIN1 in esophageal squamous cancer tissues and draining lymph nodes and their clinical significances
下载PDF
导出
摘要 目的:探讨食管鳞癌(esophageal squamous cell carcinoma,ESCC)患者肿瘤组织和引流淋巴结(tumor draining lymph node,TDLN)组织吲哚胺2,3-双加氧酶(indoleamine 2,3-dioxygenase,IDO)和桥接整合因子1(bridging integrator 1,BIN1)的表达及其在ESCC进展中的意义。方法:收集2013年4月至2014年7月在河北医科大学第四医院胸外科行肿瘤切除并经病理证实的71例ESCC患者的肿瘤组织、癌旁组织和TDLN标本,其中肿瘤组织以癌旁组织作为对照组,转移淋巴结以未转移淋巴结作为对照组,均采用Real-time PCR法和免疫组化法检测IDO和BIN1表达情况,分析两者表达的相关性及其与患者临床特征的关系。结果:与未转移淋巴结相比,转移淋巴结中IDO mRNA表达水平和蛋白阳性表达率均显著增高(0.47±0.14 vs 0.22±0.09,P<0.01;90.91%vs 67.35%,P=0.042),而BIN1 mRNA表达水平和蛋白阳性表达率均显著降低(0.15±0.11 vs 0.35±0.15,P<0.01;50.00%vs 77.55%,P=0.028)。与癌旁组织相比,肿瘤组织中IDO mRNA表达水平和蛋白阳性表达率均显著增高(0.51±0.12 vs 0.24±0.11,P<0.01;81.69%vs 22.54%,P<0.01),而BIN1 mRNA表达水平和蛋白阳性表达率均显著降低(0.17±0.10 vs 0.41±0.14,P<0.01;19.72%vs 80.28%,P=0.006)。肿瘤组织和TDLN中,IDO蛋白表达与肿瘤侵犯范围、淋巴结转移、临床分期相关,而BIN1蛋白表达与肿瘤分化程度、侵犯范围、淋巴结转移、临床分期相关。结论:ESCC患者肿瘤组织和转移TDLN中IDO表达水平显著提高、BIN1表达水平显著降低与患者临床特征密切相关,可能是影响ESCC进展的重要因素。 Objective: To investigate the expressions of indoleamine 2,3-dioxygenase (IDO) and brdging integrator 1 (BIN1) in tumor tissues and tumor draining lymph nodes (TDLNs) of the patients with esophageal squamous cell carcino- ma (ESCC) and their clinical significances. Methods: Pathological confirmed tumor tissues, carcinoma adjacent tissues and TDLNs were collected from 71 patients with ESCC who underwent tumor resection in the Department of Thoracic Sur- gery, the Fourth Hospital of Hebei Medical University between Apr. 2013 and Jul. 2014. The carcinoma adjacent tissues were set up as the control group for tumor tissue group, while the non-metastatic lymph nodes set up as the control group for metastatic lymph node group. The expression levels of IDO and BIN1 were detected with Real-time PCR and immuno- histochemistry assays, and correlation between the two expressions and their relations with clinical characteristics of the patients were analyzed. Results: Compared to the non-metastatic group, the expression level of IDO mRNA and positive rate of IDO protein were remarkably higher (0.47 ± 0.14 vs 0. 22 ± 0.09, P 〈 0.01 ; 90.91% vs 67.35 % , P = 0. 042), while the expression level of BINI mRNA and positive rate of BIN1 protein remarkably lower (0.15±0.11 vs 0. 35 ± 0. 15, P 〈0.01; 50.00% vs 77.55%, P =0. 028) in metastatic group. In addition, the expression level of IDO mRNAand positive rate of IDO protein in carcinoma tissues were significantly higher than those in para-carcinoma tissues ( 0. 51 ± 0. 12 vs 0. 24 ± 0.11, P 〈 0.01 ; 81.69 % vs 22.54 %, P 〈 0.01 ) while the expression level of BIN1 mRNA and positive rate of BIN1 protein significantly lower than those in para-carcinoma tissues (0.17 ± 0.10 vs O. 41 ±0.14, P 〈 O. 01 ; 19.72% vs 80.28%, P =0. 006). In both tumor tissues and TDLNs, the expression of IDO protein was associated with invasion range , lymph node metastasis and clinical stage of the tumors, while the expression of BIN1 protein was as- sociated with degree of differentiation, invasion range, lymph node metastasis and clinical stage of the tumors. Conclu- sion : In ESCC tumor tissues and metastatic TDLNs, the expression level of IDO was significantly up-regulated and the ex- pression level of BIN1 significantly down-regulated, which were closely associated with clinical features of the patients and might be important factors affectinz progression of ESCC.
出处 《中国肿瘤生物治疗杂志》 CAS CSCD 北大核心 2016年第2期276-281,共6页 Chinese Journal of Cancer Biotherapy
基金 国家自然科学基金青年科学基金资助项目(No.H2012206135) 河北省杰出青年基金(No.H2014206320)~~
关键词 食管鳞癌 肿瘤引流淋巴结 吲哚胺2 3-双加氧酶 桥接整合因子1 esophageal squamous cell carcinoma ( ESCC ) tumor draining lymph node ( TDLN ) indoleamine 2,5-dioxygenase (IDO) brdging integrator 1 (BIN1)
  • 相关文献

参考文献13

  • 1IRINO T, TAKEUCHI H, MATSUDA S, et al. CC-Chemoskine receptor CCR7: a key molecule for lymph node metastasis in esophageal squamous cell carcinoma [ J/OL ]. BMC Cancer, 2014, 14: 29l [2015-11-11 ]. http://bmccancer, biomedcen- tral. com/articles/10. 1186/1471-2407-14-291. DOI: 10. 1186/ 1471-2407 -14 -291.
  • 2SZMURKOWSKI J J, ZAWROCKI A, BIERNAT W. Subtypes of cytotoxie lymphocytes and natrual killer cells infiltrating cancer nests correlate with prognosis in patients with vulvar squamous cell carcinoma [ J ]. Cancer Immunol Immunother, 2014, 63 ( 3 ) : 297-303. DOI: 10. 1007/s00262-O13-1511-x.
  • 3SATO N, SAGA Y, MIZUKAMI H, et al. Downregulation of in- daleamine-2, 3-dioxygenase in cervical cancer cells suppresses tumor growth by promoting natural killer cell accumulation [J]. Oncol Rep, 2012, 28(5) : 1574-1578. DOI: 10. 3892/or. 2012. 1984.
  • 4MULLER A J, DUHADAWAY J B, DONOVER P S, et al. Inhi- bition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Binl, potentiates cancer chemo-therapy [J]. Nat Med, 2005, 11(3) : 312-319. DOI: 10. 1038/ nm1196.
  • 5PAN K, LIANG X T, ZHANG H K, et al. Characterization of bridging integrator 1 ( BIN1 ) as a potential tumor suppressor and prognostic marker in hepatocellular carcinoma [ J ]. Mol Med, 2012, 18(5) : 507-518. DO1: 10. 2119/molmed. 2011. 00319.
  • 6ZOSO A, MAZZA E M, BICCIATO S, et al. Human fibrocytic myeloid-derived suppressor cells express IDO and promote toler- ance via Treg-cell expansion [ J]. Eur J Immunol, 2014, 44 (11 ) : 3307-3319. DOI: 10. 1002/eji. 201444522.
  • 7FERNS D M, KEMA I P, BUIST M R, et al. Indoleamine 2,3- dioxygenase (IDO) metabolic activity is detrimental for cervical cancer patient survival [ J/OL ]. Oncoimmunology, 2015, 4 ( 2 ) : e981457 [2015-11-O7 ] http://www, tandfonline, eom/doi/abs/ 10. 4161/2162402x. 2014. 981457. DOI: 10. 4161/2162402x. 2014. 981457.
  • 8GAO Y F, PENG R Q, LI J, et al. The paradoxical patterns of expression of indoleamine 2,3-dioxygenase in colon cancer [ J/ OL]. J Transl Med, 2009, 7:71 E2015-11-07~ http://transla- tional-medieine, biomedeentral, eom/artieles/10. 1186/1479- 5876-7-71. DOI: 10. 1186/1479-5876-7-71.
  • 9ESMAILZADEH S, HUANG Y, SU M W, et al. BIN1 tumor sup- pressor regulates Fas/Fas ligand-mediated apoptosis through c-FLIP in cutaneous T-cell lymphoma [ J]. Leukemia, 2015, 29 (6) : 1402-1413. DOI : 10. 1038/leu. 2015.9.
  • 10SAKAMURO D, ELLIOTr K J, WECHSLER-REYA R, et al. BIN1 is a novel MYC-interacting protein with features of a tumour suppressor [ J]. Nat Genet, 1996, 14 ( 1 ) : 69-77. DOI: 10. 1038/ng0996-69.

同被引文献10

引证文献2

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部